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Adipose tissue mass can expand throughout adult life. Therefore, proliferative adipocyte precursor cells
must stand at the ready to respond to increased demand for energy storage. Recent provocative studies
have identified discrete immature cell populations from which brown and white adipocytes are derived.
This work not only brings fundamental insight into adipose tissue formation but also provides new tools to
study how adipogenesis is regulated in pathological conditions such as obesity and diabetes.Adipocytes are central to the control of energy balance and lipid
homeostasis. The ability to store excess energy in adipose tissue
is an important evolutionary adaptation. However, obesity, the
excess accumulation of adipose tissue, is a risk factor for type 2
diabetes and cardiovascular disease (Kopelman, 2000). As the
global rates of obesity are expected to rise for the foreseeable
future, this once beneficial adaptation now poses a major health
threat. Conversely, lipodystrophy also results in insulin resis-
tance, diabetes, and aberrant lipid metabolism. Thus, under-
standing the origins of adipose tissue and its links to metabolic
diseases is of enormous public interest.
In mammals, adipocytes have been classified into two distinct
types: white adipose tissue (WAT), the primary site of energy
storage, and brown adipose tissue (BAT), specialized for energy
expenditure (Spiegelman and Flier, 2001). White adipocytes
express cell type-selective machinery required for triglyceride
synthesis from lipoprotein-derived fatty acids as well as hor-
mone-stimulated glucose uptake and lipolysis. In addition, adi-
pocytes have an endocrine role, producing adipokines such as
TNFa, leptin, resistin, RBP4, and adiponectin that modulate sys-
temic metabolism (Waki and Tontonoz, 2007). This endocrine
function is not selective for white fat cells, as many of these
factors are also made by brown adipocytes. WAT is also an
important target for the action of human therapeutics—the thia-
zolidinedione (TZD) antidiabetic drugs being the most notable
example (Nolan et al., 1994). The inability to properly store tri-
glycerides in adipose tissue results in adverse effects on glucose
metabolism in the liver and skeletal muscle (Saltiel and Kahn,
2001). TZDs may act in large measure by promoting appropriate
lipid storage in adipocytes and diverting excess lipid away from
skeletal muscle.
In contrast with WAT, the physiological role of BAT is to me-
tabolize fatty acids and generate heat (Spiegelman and Flier,
2001). This specialized function of brown fat cells derives from
high mitochondrial content and the ability to uncouple cellular
respiration through the action of uncoupling protein-1 (UCP-1).
Due to these functional differences, the balance between WAT
and BAT affects systemic energy balance and may contribute
to the development of obesity. Although the role of BAT in adult
humans for many years had been considered to be insignificant,
this is now the subject of significant debate in the adipocyte bi-
ology community. Recent studies have shown that brown adipo-
cytes are dispersed throughout the human adipose tissues and454 Cell Metabolism 8, December 3, 2008 ª2008 Elsevier Inc.are metabolically active (Nedergaard et al., 2007). Modulation
of brown adipocyte activity has been proposed as a potential
strategy to combat obesity and its associated diseases. Dissec-
tion of the regulatory pathways that control BAT andWAT devel-
opment may therefore uncover new opportunities for interven-
tion in metabolic diseases.
The transcriptional cascade required for adipocyte differentia-
tion has been the subject of intense investigation and has been
reviewed extensively elsewhere (Gesta et al., 2007; Tontonoz
and Spiegelman, 2008). Briefly, the adipogenic program centers
on the expression and activation of PPARg, a lipid-activated nu-
clear hormone receptor that serves as the master transcriptional
regulator of adipogenesis. PPARg heterodimerizes with RXR and
regulates downstream target gene expression leading to the
formation of differentiated adipocytes. Three members of the
C/EBP family (a, b, d) also play important roles in differentiation
and act in a feedback loop to regulate PPARg expression. In
addition to these central players, Krox20, KLFs, and EBFs
have been reported to promote differentiation, while GATA2/3,
KLF2, HES-1, and TCF/LEF are inhibitory (Gesta et al., 2007;
Tontonoz and Spiegelman, 2008).
Despite substantial progress in defining adipocyte transcrip-
tional control mechanisms, we still have only limited information
regarding the identity and localization of adipocyte precursors
in vivo. Althoughmost WAT development occurs during late pre-
natal and early postnatal life, it retains the ability to expand dur-
ing adult life when energy intake exceeds energy expenditure.
This is accomplished through both increased adipocyte num-
bers (hyperplasia) as well as increased adipocyte size (hypertro-
phy) (Hirsch and Batchelor, 1976). Furthermore, recent studies
suggest that approximately 10% of the body’s fat cells are re-
generated each year (Spalding et al., 2008). However, mature
adipocytes are postmitotic. In order to support the expansion
of adipose tissue mass if needed and to maintain adipose dy-
namics in adult, proliferative adipocyte precursor cellsmust exist
and be poised to respond to metabolic demands. A number of
laboratories have embarked upon the search for such precur-
sors, and these efforts have recently begun to yield hefty fruit.
In a recent publication in Science, Graff and colleagues
generated PPARg-reporter strains based on the reasoning that
PPARg expression is the defining feature of the adipocyte
(Tang et al., 2008). To perform lineage analysis, the authors gen-
erated PPARg-R26R (PPARg-tTA [tet TransActvator]; TRE-CRE
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response to Cre]) mice. Surprisingly, the expression of lacZ from
the PPARg-R26R allele within adipose depots remained
relatively constant at postnatal day 30 (P30) despite the admin-
istration of the tTA inhibitor doxycycline from P1. This result
suggested that even at P1 there were PPARg-cells already pres-
ent and appeared to contradict the classical idea that adipocyte
formation occurs later during development. However, it should
be noted that it has been clear to adipocyte researchers for
some time that undifferentiated preadipocytes express low
levels of PPARg and can be driven to differentiate simply by pro-
viding PPARg ligand (Tontonoz and Spiegelman, 2008). Tang
et al. verified their result using a second reporter, PPARg-GFP
(PPARg-tTA; TRE-H2B-GFP), that is stably expressed in postmi-
totic cells but whose signal becomes attenuated in proliferating
cells upon tTA inhibition. This approach also confirmed the
proliferative capacity of these GFP+ PPARg-expressing cells.
Further analysis of these GFP+ cells found in the adipose
stroma-vascular fraction by FACS revealed high expression of
the preadipocyte markers Pref1, GATA3, Wisp2, Smo, and Gli3
but lower levels of mature adipocyte markers. These GFP+ puta-
tive precursor cells were capable of differentiating into mature
white adipocytes in vitro and formed ectopic GFP+ fat when
transplanted into nude mice.
Previous work had postulated that precursors may exist in the
adipose vasculature (Sengenes et al., 2005). In support of this
idea, Tang et al. localized their GFP+ PPARg-expressing precur-
sor cells to the vasculature. Furthermore, these GFP+ cells colo-
calized with so-called mural cells as shown by SMA, PDGFRb,
and NG2 staining. The authors also found that PDGFRb+ cells
from adipose tissue exhibited adipogenic potential both in vitro
and in vivo. On the other hand, PDGFRb+ cells from other tissues
and SM22+ (a vascular smooth muscle cell marker) cells did not
have adipogenic potential, suggesting that the adipocyte precur-
sor cells are a discrete subset of mural cells.
Working independently, Friedman and colleagues have also
reported in a recent publication in Cell the isolation of white ad-
ipocyte precursor cells (Rodeheffer et al., 2008). Using FACS to
analyze the expression of cell-surface and stem cell markers,
these investigators isolated two cell populations, one CD24+
(lin:CD29+:CD34+:Sca-1+:CD24+) and one CD24, that were
capable of developing into adipocytes in vitro. Remarkably, the
precursor cells isolated by the Graff group were also found to
display similar markers, suggesting that the two laboratories
have identified similar (if not identical) precursor populations.
To determine whether their FACS-sorted subpopulations
could develop into fat cells in vivo, Rodeheffer et al. transplanted
50,000 GFP-labeled donor cells into the fat depots of A-Zip lip-
odystrophic mice (Rodeheffer et al., 2008). These fatless mice
express a dominant-negative bHLH protein specifically in adipo-
cytes and exhibit a lipoatrophic diabetic phenotype (Moitra et al.,
1998). The authors found that injection of the CD24+GFP+ pre-
cursor cells led to the development of fat depots showing normal
adipocyte morphology that were almost entirely GFP+. However,
the CD24 and CD34 populations failed to reconstitute WAT
after transplantation into A-ZIP mice, suggesting that CD24+
populations are the true source of white adipocyte precursors
in vivo. The question of what is special about the lipoatrophic
background that allows these cells to develop into adipocytesremains to be addressed. It would also be interesting to know
whether cells with similar surface marker expression derived
from other tissues could also give rise to adipocytes.
Rodeheffer et al. also used noninvasive imaging methods, as
previously developed by this group, to follow the maturation of
adipocyte precursors in a living animal (Birsoy et al., 2008).
CD24+ cells derived from mice expressing luciferase from the
adipocyte-specific leptin promoter were injected into the fat de-
pots of A-Zip mice. In vivo, the CD24+ cells displayed a steady
increase in luciferase expression beginning 2 weeks after injec-
tion. Interestingly, luciferase activity was detected only in adi-
pose tissue, demonstrating the unique developmental potential
of this cell population. Moreover, consistent with the expected
increase in adipocyte number in response to dietary challenge,
a robust luciferase signal from CD24+ cells was observed follow-
ing injection into high-fat-fed mice but not in chow-fed mice.
In prior studies of A-Zip mice, Reitman and colleagues were
able to correct the insulin resistance and hyperglycemia by
transplanting a large mass of normal WAT (1 g) (Gavrilova
et al., 2000). Remarkably, in their current work Friedman and col-
leagues showed that injection of only 50,000 CD24+ cells en-
abled the formation of normal-sized WAT depots and rescued
the lipodystrophic phenotype. Plasma glucose and insulin levels
in A-Zipmice injectedwith CD24+ cells were also normalized and
the plasma level of adiponectin, an adipokine secreted fromma-
ture fat, was increased. These data clearly established that the
fat cells reconstituted from CD24+ cells are functional. The iden-
tification of adipocyte precursor cells by both of these research
teams may lead to a better understanding of adipose tissue for-
mation and provide the tools to study factors that modulate for-
mation of adipose tissue in pathological contexts.
Adipose tissues, muscle, and bone originate from the meso-
derm. The prevailing model has held that a common meso-
derm/mesenchymal stem cell (MSC) gives rise to bone, muscle,
WAT, and BAT in response to appropriate developmental cues
(Figure 1). An intermediate step in this developmental program
has been assumed to be the differentiation of a common adipose
precursor cell capable of giving rise to both WAT and BAT. One
observation pointing to the possible existence of such a common
precursor is the ability of WAT to transdifferentiate into BAT un-
der certain experimental conditions. However, recent work by
Timmons and colleagues strongly argued that brown and white
preadipocytes are distinct (Timmons et al., 2007). This observa-
tion was verified and extended by Spiegelman and colleagues,
who showed that WAT and BAT in fact are derived from distinct
precursor populations (Seale et al., 2008). These authors
showed that skeletal muscle progenitor cells can give rise to
either muscle cells or brown fat cells, but not white fat cells.
Seale et al. further showed that the decision of this precursor
to becomemuscle or BAT is controlled by the transcription factor
PRDM16. Expression of PRDM16 causesMyf5-expressingmus-
cle precursors to commit to becoming brown fat cells, whereas
reduction of PRDM16 expression by shRNA targeting induces
themyogenic differentiation program. Interestingly, other groups
had previously observed that myogenin-deficient neonatal mice
not only have less muscle but also exhibit an accumulation of
brown fat cells in areas where muscle would normally develop
(Hasty et al., 1993). Also consistent with the idea of a common
muscle and BAT precursor is the fact that muscle performsCell Metabolism 8, December 3, 2008 ª2008 Elsevier Inc. 455
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Mesenchymal stem cells give rise to precursor cells of bone, muscle, and fat cells under appropriate conditions. PPARg+ CD24+ white adipocyte precursor cells
reside in mural cell compartments of the adipose vasculature.White adipocyte differentiation is driven by the transcription factors PPARg and C/EBPs, giving rise
to triglyceride-storing WAT. This proliferating, WAT precursor cell population continually reconstitutes WAT depots throughout adult life and can respond to
increased demand for energy storage with increased differentiation. Brown fat cells share precursors (Myf5+) with muscle cells but not with white adipocytes.
Induction of PRDM16 expression in Myf5+ cells directs them to develop into brown fat cells. In the absence of PRDM16, these precursor cells will develop
into muscle cells under the influence of the transcription factors myogenin and MyoD. PRDM16 is able to interact with PGC-1 and CtBPs to activate brown
fat genes and suppress white fat genes, respectively. The cofactor RIP140 and CtBPs can also suppress mitochondrial gene expression in white adipocytes.
An outstanding issue is whether ‘‘transdifferentiation’’ between WAT and BAT occurs in physiological contexts.BAT-like function in some species. For example, birds are home-
otherms dependent on the expression of UCP in muscle for ther-
moregulation (Mozo et al., 2005). The discovery that muscle and
BAT share common progenitor cells may also help to explain the
functional dimorphism of adipose tissues, with WAT acting pri-
marily to storage lipid and BAT serving to metabolize lipids to
produce heat. The work of Spiegelman and colleagues provides
a vivid illustration of the axiom that looks can be deceiving. Al-
though the WAT and BAT are superficially similar in that they
both contain lipid droplets, they appear to stem from divergent
developmental programs.
Investigation of their developmental origins will undoubtedly
lead to better understanding of WAT and BAT biology. Looking
further into the future, it is intriguing to contemplate potential
translational applications of these discoveries for the treatment
of metabolic diseases. However, the journey toward this goal
must begin with the investigation of a number of outstanding
questions. For example, are there two routes toward BAT forma-
tion (i.e., one from muscle and one from transdifferentiated
WAT)? When do white and brown precursor cells arise during
embryonic development? Are theWAT adipocyte precursor cells
identified by Friedman and Graff and the muscle/BAT precursor
identified by Spiegelman derived from a common mesenchymal
cell? What are the molecular determinants that control PRDM16
expression in BAT precursors and PPARg expression in WAT
precursors? Can we identify small molecules that modulate the456 Cell Metabolism 8, December 3, 2008 ª2008 Elsevier Inc.development of BAT and WAT from precursor cells? Addressing
these and other issues may provide the foundation for the devel-
opment of new approaches for the therapeutic manipulation of
energy balance and the prevention or treatment of metabolic
diseases.
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